Human papillomavirus (HPV) vaccine policy and evidence-based medicine: Are they at odds?

Annals of Medicine

Volumn 45, Issue 2, 2013, Pages 182-193

  Tomljenovic, Lucija ^a   Shaw, Christopher A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cervarix; Cervical cancer; Gardasil; HPV vaccines; Informed consent; Vaccine adverse reactions

Indexed keywords

WART VIRUS VACCINE;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; AMYOTROPHIC LATERAL SCLEROSIS; ANAPHYLAXIS; AUTOIMMUNE DISEASE; CANCER INCIDENCE; CANCER MORTALITY; CHRONIC FATIGUE SYNDROME; CONVULSION; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FACIAL NERVE PARALYSIS; FAINTNESS; FEMALE; FEVER; GENOTYPE; HEADACHE; HEALTH CARE POLICY; HOSPITALIZATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFORMED CONSENT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; LUNG EMBOLISM; MEDICAL ETHICS; META ANALYSIS (TOPIC); MULTIPLE SCLEROSIS; MYELITIS; NAUSEA; NEURITIS; OPSOCLONUS MYOCLONUS SYNDROME; ORTHOSTATIC HYPOTENSION; PANCREATITIS; PARALYSIS; PARESTHESIA; PRACTICE GUIDELINE; PRECANCER; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEXUAL TRANSMISSION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VISUAL IMPAIRMENT;

DEVELOPING COUNTRIES; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRACTICE GUIDELINES AS TOPIC; UTERINE CERVICAL NEOPLASMS;

EID: 84873382773     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2011.645353     Document Type: Review

References (107)

1. Food and Drug Administration (FDA). Workshop on Non-clinical Safety Evaluation of Preventative Vaccines: Recent Advances and Regulatory Considerations. 2002 [cited 2011 May 30]. Available from: http://www.fda.gov/ downloads/biologicsbloodvaccines/newsevents/workshopsmeetingsconferences/ transcriptsminutes/ucm054459.pdf
2. The Australian Immunisation Handbook, 9th edition. 1.3. Pre-vaccination Procedures. 1.3.3 Valid consent [cited 2011 September 15]. Available from: http://www.health.gov.au/internet/immunise/publishing. nsf/Content/handbook- consent
3. UK Guidance on Best Practice in Vaccine Administration. 2001 [cited 2011 September 15]. Available from: http://www.rcn.org.uk/-data/assets/pdf-fi le/0010/78562/001981.pdf
4. Centers for Disease Control and Prevention. Vaccine Information Statements (VISs). Last modifi ed December 6, 2010 [cited 2011 April 5]. Available from: http://www.cdc.gov/vaccines/pubs/vis/vis-faqs.htm
5. Merck&Co. Protection with Gardasil [cited 2011 July 20]. Available from:http://www.gardasil.com/what-is-gardasil/cervical-cancer-vaccine/index.html
6. Centers for Disease Control and Prevention. Information from FDA and CDC on Gardasil and its Safety (Archived), 2008 [cited 2011 January 25]. Available from: http://www.cdc.gov/vaccinesafety/Vaccines/HPV/HPVArchived.html
7. Centers for Disease Control and Prevention (CDC). Reports of Health Concerns Following HPV Vaccination. Last updated: June 28, 2011[cited 2011 July 22]. Available from: http://www.cdc.gov/vaccinesafety/vaccines/hpv/gardasil.html
8. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, IversenOE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459-66.
9. De Carvalho N, Teixeira J, Roteli-Martins CM, Naud P, De Borba P, Zahaf T, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine. 2010;28:6247-55.
10. Harper DM, Williams KB. Prophylactic HPV vaccines: current knowledge of impact on gynecologicpremalignancies. Discov Med. 2010;10: 7-17.
11. Haug C. The risks and benefi ts of HPV vaccination. JAMA. 2009;302: 795-6.
12. Flogging gardasil. Nat Biotechnol. 2007;25:261.
13. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalenthuman papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56:1-24.
14. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): fi nal analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301-14.
15. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. NEngl J Med. 2007;356:1915-27.
16. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, D é sy M, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. JInfect Dis. 1999;180:1415-23.
17. HoGY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. NEngl J Med. 1998;338:423-8.
18. Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998;132:277-84.
19. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12:186-92.
20. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al.; FUTURE I Investigators.Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. NEngl J Med. 2007;356:1928-43.
21. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of human papillomavirus 16/18 L1viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298:743-53.
22. Food and Drug Administration (FDA). Gardasil (Human Papillomavirus Vaccine) Questions and Answers, June 8, 2006 [cited 2011 September 27]. Available from: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ QuestionsaboutVaccines/ucm096052.htm
23. Medicines and Healthcare productsRegulatory Agency (MHRA). Paper provided by MHRA for Joint Committee on Vaccination and Immunisation June 2010: Vaccine associated suspected adverse reactions reported via the Yellow Card scheme during 2009 [cited 2011 July 17]. Available from: http://www.dh.gov.uk/prod- consum-dh/groups/dh-digitalassets/@dh/@ab/documents/digitalasset/dh-118753.pdf
24. Irish Medicines Board (IMB). Update on national monitoring experience with Gardasil. 11th November 2010 [cited 2011 July 17]. Available from: http://www.imb.ie/images/uploaded/documents/IMB-Gardasil-WebUpdate-11Nov2010.pdf
25. Campos NG, Kim JJ, Castle PE, Ortendahl JD, O' Shea M, Diaz M, et al. Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer. 2011 Jun 29. [Epub ahead of print]
26. Lawrence G, Gold MS, Hill R, Deeks S, Glasswell A, McIntyre PB. Annual report: Surveillance of adverse events following immunisation in Australia, 2007. Commun Dis Intell. 2008;32(4)371-87.
27. National Vaccine Information Center. An Analysis by the National Vaccine Information Center of Gardasil &Menactra Adverse Event Reports to the Vaccine Adverse Events Reporting System (VAERS). February 2009 [cited 2011 January 25]. Available from: http://www. nvic.org/Downloads/ NVICGardasilvsMenactraVAERSReportFeb-2009u.aspx
28. Menzies R, Mahajan D, Gold MS, Roomiani I, McIntyre P, Lawrence G. Annual report: Surveillance of adverse events following immunisation in Australia, 2008. Commun Dis Intell. 2009;33:365-81. Available from: http://www.health.gov. au/internet/main/publishing.nsf/Content/cdi3304
29. Mahajan D, Roomiani I, Gold MS, Lawrence GL, McIntyre PB, Menzies RI. Annual report: Surveillance of adverse events following immunisation in Australia, 2009. Comm Dis Intell. 2010;34:259-76. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cdi3403-1
30. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302:750-7.
31. Medicines and Healthcare productsRegulatory Agency (MHRA). Paper provided by MHRA for Joint Committee on Vaccination and Immunisation June 2009: Vaccine associated suspected adverse reactions reported via the Yellow Card scheme during 2008 [cited 2011 July 17]. Available from: http://www.dh.gov.uk/prod- consum-dh/groups/dh-digitalassets/@dh/@ab/documents/digitalasset/dh-110017.pdf
32. Database of the Netherlands Pharmacovigilance Centre Lareb. Overview adverse events following immunization in association with Cervarix. February 3, 2010 [cited 2011 July 24]. Available from: http://www.lareb.nl/documents/kwb- 2010-2-cerva.pdf
33. Irish Medicines Board (IMB). Update on national monitoring experience with Gardasil. 9th February 2011 [cited 2011 July 17]. Available from: http://www.imb.ie/images/uploaded/documents/IMB-Gardasil-WebUpdate-09Feb2011.pdf
34. Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSAPS). Vaccinscontre les infections d û es à certains papillomavirus humains (HPV). Gardasil ®: Troisi è mebilan du plan de gestion des risqueseurop é enet national (12/07/2011) [cited 2011 July 24]. Available from: http://www.afssaps.fr/Dossiers-thematiques/Vaccins/Vaccins-contre-les- infections-dues-a-certains-papillomavirus-humains-HPV/28offset29/2
35. CDC WONDER VAERS Request [cited 2011 September 15]. Available from: http://wonder.cdc.gov/vaers.html
36. Chustecka Z. HPV Vaccine: Debate Over Benefi ts, Marketing, and New Adverse Event Data. Medscape Med News. 2009[cited 2011 January 25]. Available from: http://www.medscape.com/viewarticle/707634
37. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee (VRBPAC) Background Document: Gardasil ™ HPV Quadrivalent Vaccine. May 18, 2006 VRBPAC Meeting [cited 2011 September 15]. Available from: http://www.fda.gov/ohrms/dockets/ac/06/briefi ng/2006-4222B3.pdf
38. Health Canada. Human Papillomavirus (HPV). Updated August 2010 [cited 2011 April 4]. Available from: http://www.hc-sc.gc.ca/hl-vs/iyhvsv/diseases- maladies/hpv-vph-eng.php
39. Australian Government, Department of Health and Ageing, Therapeutic Goods Administration. Human papillomavirus vaccine (GARDASIL), Advice from the Therapeutic Goods Administration. Updated 24 June 2010 [cited 2011 July 24]. Available from: http://www.tga.gov.au/safety/alerts-medicine-gardasil-070624.htm
40. Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 2008;26:6630-8.
41. Shoenfeld Y, Agmon-Levin N. ' ASIA'-Autoimmune/infl ammatory syndrome induced by adjuvants. J Autoimmun. 2011;36:4-8.
42. Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus. 2009;18:1217-25.
43. Cohen AD, Shoenfeld Y. Vaccine-induced autoimmunity. J Autoimmun. 1996;9:699-703.
44. A gmon-Levin N, Paz Z, Israeli E, Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol. 2009;5:648-52.
45. Gandey A. Report of Motor Neuron Disease After HPV Vaccine. Medscape Med News. 2009 [cited 2011 January 25]. Available from: http://www.medscape.com/ viewarticle/711461
46. Löwer J. Can we still recommend HPV vaccination? MMWFortschr Med. 2008;150:6.
47. Mendoza Plasencia Z, Gonzalez Lopez M, Fernandez Sanfi el ML, Muniz Montes JR. [Acute disseminated encephalomyelitis with tumefactive lesions aft er vaccination against human papillomavirus]. Neurologia. 2010;25:58-9.
48. Wildemann B, Jarius S, Hartmann M, RegulaJU, Hametner C. Acute disseminated encephalomyelitis following vaccination against human papilloma virus. Neurology. 2009;72:2132-3.
49. Schaffer V, Wimmer S, Rotaru I, Topakian R, Haring HP, Aichner FT. HPV vaccine: a cornerstone of female health a possible cause of ADEM? J Neurol. 2008;255:1818-20.
50. Sutton I, Lahoria R, Tan IL, Clouston P, Barnett MH. CNS demyelination and quadrivalent HPV vaccination. Mult Scler. 2009;15:116-9.
51. Chang J, Campagnolo D, Vollmer TL, Bomprezzi R. Demyelinating disease and polyvalent human papilloma virus vaccination. J Neurol-Neurosurg Psychiatry. 2010:1-3.
52. A lvarez-Soria MJ, Hernandez-Gonzalez A, Carrasco-Garcia de Leon S, Del Real-Francia MA, Gallardo-AlcanizMJ, Lopez-Gomez JL. [Demyelinating disease and vaccination of the human papillomavirus]. Rev Neurol. 2011;52:472-6.
53. McCarthy JE, Filiano J. Opsoclonus Myoclonus aft er human papilloma virus vaccine in a pediatric patient. Parkinsonism Relat Disord. 2009;15: 792-4.
54. Mosnaim AD, Abiola R, Wolf ME, Perlmuter LC. Etiology and risk factors for developing orthostatic hypotension. Am J Ther. 2009;17:86-91.
55. Debeer P, De Munter P, Bruyninckx F, Devlieger R. Brachial plexus neuritis following HPV vaccination. Vaccine. 2008;26:4417-9.
56. Cohen SM. Multiple evanescent white dot syndrome aft er vaccination for human papilloma virus and meningococcus. JPediatr Ophthalmol Strabismus. 2009:1-3.
57. Das A, Chang D, Biankin AV, Merrett ND. Pancreatitis following human papillomavirus vaccination. Med J Aust. 2008;189:178.
58. Brotherton JM, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Campbell-Lloyd S. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ. 2008;179:525-33.
59. Blitshteyn S. Postural tachycardia syndrome aft er vaccination with Gardasil [letter to the editor]. Eur J Neurol. 2010;17:e52.
60. Dale RC, Brilot F, Banwell B. Pediatric central nervous system infl ammatory demyelination: acute disseminated encephalomyelitis, clinically isolated syndromes, neuromyelitisoptica, and multiple sclerosis. Curr Opin Neurol. 2009;22:233-40.
61. Low PA, Sandroni P, Joyner M, Shen WK. Postural tachycardia syndrome (POTS). JCardiovasc Electrophysiol. 2009;20:352-8.
62. Medicines and Healthcare products Regulatory Agency (MHRA). Suspected adverse reactions received by the MHRA. Cervarix Human papillomavirus (HPV) vaccine (as of 29 July 2010) [cited 2011 July 24]. Available from: http://www.mhra.gov.uk/PrintPreview/DefaultSplashPP/CON023340? ResultCount-10&DynamicListQuery-&DynamicList-SortBy-xCreationDate& DynamicListSortOrder-Desc&Dynamic ListTitle-&PageNumber-1&Title- Human20papillomavirus20 28HPV2920vaccine
63. Food and Drug Administration. Inside Clinical Trials: Testing Medical Products in People. Last updated May 2009 [cited 2011 April 4]. Available from: http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143531.htm
64. Golomb BA, Erickson LC, Koperski S, Sack D, Enkin M, Howick J. What ' s in placebos: who knows? Analysis of randomized, controlled trials. Ann Intern Med. 2010;153:532-5.
65. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757-65.
66. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367: 1247-55.
67. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271-8.
68. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006;107:18-27.
69. Munoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009;373:1949-57.
70. Bishop NJ, Morley R, Day JP, Lucas A. Aluminum neurotoxicity in preterm infants receiving intravenous-feeding solutions. NEngl J Med. 1997;336:1557-61.
71. Walton JR. Functional impairment in aged rats chronically exposed to human range dietary aluminum equivalents. Neurotoxicology. 2009;30: 182-93.
72. Tomljenovic L. Aluminum and Alzheimer' s disease: aft er a century of controversy, is there a plausible link? J Alzheimers Dis. 2011;23:567-98.
73. Couette M, Boisse MF, Maison P, Brugieres P, Cesaro P, Chevalier X, et al. Long-term persistence of vaccine-derived aluminum hydroxide is associated with chronic cognitive dysfunction. JInorg Biochem. 2009;103:1571-8.
74. Authier FJ, Cherin P, Creange A, Bonnotte B, Ferrer X, Abdelmoumni A, et al. Central nervous system disease in patients with macrophagicmyofasciitis. Brain. 2001;124(Pt 5):974-83.
75. Exley C, Swarbrick L, GherardiRK, AuthierFJ. Arole for the body burden of aluminium in vaccine-associated macrophagicmyofasciitis and chronic fatigue syndrome. Med Hypotheses. 2009;72:135-9.
76. Gherardi RK, Coquet M, Cherin P, Belec L, Moretto P, Dreyfus PA, Pellissier et al. Macrophagicmyofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain. 2001;124(Pt 9):1821-31.
77. Shaw CA, PetrikMS. Aluminum hydroxide injections lead to motor defi cits and motor neuron degeneration. JInorg Biochem. 2009;103: 1555-62.
78. Petrik MS, Wong MC, Tabata RC, Garry RF, Shaw CA. Aluminum adjuvant linked to Gulf War illness induces motor neuron death in mice. Neuromolecular Med. 2007;9:83-100.
79. Tomljenovic L, Shaw CA. Do aluminum vaccine adjuvants contribute to the rising prevalence of autism? J Inorg Biochem. 2011;105:1489-99.
80. Tomljenovic L, Shaw CA. Aluminum vaccine adjuvants: are they safe? Curr Med Chem. 2011;18:2630-7.
81. Exley C. Aluminium-based adjuvants should not be used as placebos in clinical trials. Vaccine. 2011;29:9289.
82. M erck&Co. Gardasil product sheet. Date of Approval 2006, p. 1-2 6 [cited 2011 July 25]. Available from: http://www.fda.gov/downloads/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf
83. Lu B, Kumar A, Castellsague X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis. 2011;11:13.
84. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a metaanalysis. Br J Cancer. 2003;88:63-73.
85. Castle PE. Beyond human papillomavirus: the cervix, exogenous secondary factors, and the development of cervical precancer and cancer. JLow Genit Tract Dis. 2004;8:224-30.
86. Harper DM, Nieminen P, Paavonen J, Lehtinen M. Cervical cancer incidence can increase despite HPV vaccination. Lancet Infect Dis. 2010;10:594-5; author reply 595.
87. Lippman A, Melnychuk R, Shimmin C, Boscoe M. Human papillomavirus, vaccines and women ' s health: questions and cautions. CMAJ. 2007;177:484-7.
88. Engeland A, Haldorsen T, Tretli S, Hakulinen T, Hö r te LG, Luostarinen T, et al. Prediction of cancer mortality in the Nordic countries up to the years 2000 and 2010, on the basis of relative survival analysis. Acollaborative study of the fi ve Nordic Cancer Registries. APMIS Suppl. 1995;49:1-161.
89. Laukkanen P, Koskela P, Pukkala E, Dillner J, Läärä E, Knekt P, et al. Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. JGen Virol.2003;84(Pt 8): 2105-9.
90. Fagot JP, Boutrelle A, Ricordeau P, Weill A, Allemand H. HPV vaccination in France: uptake, costs and issues for the National Health Insurance. Vaccine. 2011;29:3610-6.
91. Sharma M, Ortendahl J, van der Ham E, Sy S, Kim J. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Th ailand. BJOG. 2011 Apr 12. [Epub ahead of print]
92. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. NEngl J Med. 2008;359:821-32.
93. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009;339:b3884.
94. deKok IM, van Ballegooijen M, Habbema JD. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. JNatl Cancer Inst. 2009;101:1083-92.
95. The New York Times. U.S. Approves Use of Vaccine for Cervical Cancer. June 9, 2006 [cited 2011 September 14]. Available from: http://www.nytimes.com/ 2006/06/09/health/09vaccine.html?ft a-y
96. Judicial Watch Special Report. Examining the FDA' s HPV Vaccine Records Detailing the Approval Process, Side-Effects, Safety Concerns and Marketing Practices of a Large-Scale Public Health Experiment. June 30, 2008 [cited 2011 September 14]. Available from: http://www.judicialwatch. org/documents/2008/ JWReportFDAhpvVaccineRecords.pdf
97. Food and Drug Administration (FDA). FDA Science and Mission at Risk, Report of the Subcommittee on Science and Technology 2007 [cited 2010 December 12]. Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4329b- 02-01-FDA20Report20 on20Science20and20Technology.pdf
98. Rothman SM, Rothman DJ. Marketing HPV vaccine: implications for adolescent health and medical professionalism. JAMA. 2009;302: 781-6.
99. Sarojini NB, Srinivasan S, Madhavi Y, Srinivasan S, Shenoi A. The HPV vaccine: science, ethics and regulation.EconomPolit Weekly. 2010;45: 27-34.
100. Sengupta A, Shenoi A, Sarojini NB, Madhavi Y. Human papillomavirus vaccine trials in India. Lancet Infect Dis. 2011;377:719.
101. L egifrancegouv. Le Service Public De La Diffusion Du Droit. D é cision du 31 ao û t 2010 interdisantunepublicit é pour un m é dicamentmentionn é e à l ' article L. 5122-1, premier alin é a, du code de la sant é publiquedestiné e aux personneshabilité es à prescrireoudélivrercesmé dicamentsou à les utiliserdansl'exercice de leur art [cited 2011 January 26]. Available from: http://www.legifrance.gouv.fr/affichTexte.do;jsessionid-? cidTex te-JORFTEXT000022839429&dateTexte&oldAction-rechJO& categorieLien-id
102. McGee G, Johnson S. Has the spread of HPV vaccine marketing conveyed immunity to common sense? Am J Bioeth. 2007;7:1-2.
103. Telethon Institute for Child Health Research. Perth women needed for international cervical cancer study, 12 April, 2006 [cited 2011 July 26]. Available from: http://www.ichr.uwa.edu.au/media/478
104. World Medical Association (WMA) Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects [cited 2011 April 6]. Available from: http://www.wma.net/en/30publications/10policies/b3/
105. W HO/ICO Information Centre on Human Papilloma Virus and Cervical Cancer [cited 2011 July 20]. Available from: http://apps.who.int/hpvcentre/statistics/ dynamic/ico/SummaryReportsSelect.cfm
106. Food and Drug Administration (FDA). CFR-Code of Federal Regulations Title 21 [cited 2011 September 19]. Available from: http://www.accessdata.fda.gov/ scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm? fr-314.80
107. W HO/ICO HPV Information Centre. Human papillomavirus and related cancers. Summary report update. November 15, 2010 [cited 2011 July 21]. Available from: http://apps.who.int/hpvcentre/statistics/dynamic/ico/country- pdf/XWX.pdf?CFID-5169709&CFTOKEN-39667351